Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
- PMID: 17604802
- DOI: 10.1016/S0140-6736(07)61016-2
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
Abstract
Meningococcus, an obligate human bacterial pathogen, remains a worldwide and devastating cause of epidemic meningitis and sepsis. However, advances have been made in our understanding of meningococcal biology and pathogenesis, global epidemiology, transmission and carriage, host susceptibility, pathophysiology, and clinical presentations. Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these advances. Importantly, the next generation of meningococcal conjugate vaccines for serogroups A, C, Y, W-135, and broadly effective serogroup B vaccines are on the horizon, which could eliminate the organism as a major threat to human health in industrialised countries in the next decade. The crucial challenge will be effective introduction of new meningococcal vaccines into developing countries, especially in sub-Saharan Africa, where they are urgently needed.
Similar articles
-
Conquering the meningococcus.FEMS Microbiol Rev. 2007 Jan;31(1):3-14. doi: 10.1111/j.1574-6976.2006.00051.x. FEMS Microbiol Rev. 2007. PMID: 17233633 Review.
-
Serogroup B meningococcal vaccines.Curr Opin Investig Drugs. 2006 Aug;7(8):733-9. Curr Opin Investig Drugs. 2006. PMID: 16955685 Review.
-
The epidemiology of meningococcal disease and the impact of vaccines.Expert Rev Vaccines. 2010 Mar;9(3):285-98. doi: 10.1586/erv.10.3. Expert Rev Vaccines. 2010. PMID: 20218857 Review.
-
The implications of vaccines for prevention of bacterial meningitis.Curr Opin Neurol. 2010 Jun;23(3):319-24. doi: 10.1097/WCO.0b013e3283381751. Curr Opin Neurol. 2010. PMID: 20173637 Review.
-
Toward a meningitis-free world.Sci Transl Med. 2012 Feb 29;4(123):123ps5. doi: 10.1126/scitranslmed.3003859. Sci Transl Med. 2012. PMID: 22378923
Cited by
-
Genetic characterization of Neisseria meningitidis isolates recovered from patients with invasive meningococcal disease in Lithuania.Front Cell Infect Microbiol. 2024 Oct 14;14:1432197. doi: 10.3389/fcimb.2024.1432197. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39469455 Free PMC article.
-
Factor H binding protein (FHbp): An evaluation of genotypic diversity across Neisseria meningitidis serogroups.Hum Vaccin Immunother. 2024 Dec 31;20(1):2409502. doi: 10.1080/21645515.2024.2409502. Epub 2024 Oct 10. Hum Vaccin Immunother. 2024. PMID: 39387286 Free PMC article. Review.
-
[False negative result in both multiplex and monoplex PCR in a case of Neisseria meningitidis bacteremia. Diagnostic, therapeutic and epidemiological implications].Rev Esp Quimioter. 2024 Oct;37(5):427-428. doi: 10.37201/req/040.2024. Epub 2024 Jul 10. Rev Esp Quimioter. 2024. PMID: 38984406 Free PMC article. Spanish. No abstract available.
-
Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.Pharmacoecon Open. 2024 Jul;8(4):539-557. doi: 10.1007/s41669-024-00488-5. Epub 2024 May 23. Pharmacoecon Open. 2024. PMID: 38780884 Free PMC article.
-
Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine.JCI Insight. 2024 Apr 11;9(10):e177182. doi: 10.1172/jci.insight.177182. JCI Insight. 2024. PMID: 38775152 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
